Home › Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute
 

Keywords :   


Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

2016-03-25 15:53:27| Biotech - Topix.net

The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni.

Tags: pay million drug ordered

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05NABC hosts foreign animal disease tabletop exercise
20.05NABC hosts foreign animal disease tabletop exercise
20.05Printed Easy increases capacity by 300% with Durst
More »